Related Experiment Video
Updated: Oct 17, 2025

05:08
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
11.4K
Histamine receptors in heart failure
1Kolling Institute, St Leonards, Australia. scott.levick@sydney.edu.au.
Heart Failure Reviews
|October 8, 2021
Summary
Histamine receptors play complex roles in heart failure. Targeting these receptors, particularly histamine 1 and 2, offers potential therapeutic strategies for heart conditions.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Histamine, a biogenic amine, mediates diverse physiological effects through four G-protein-coupled receptors.
- Histamine receptors (H1R, H2R, H3R, H4R) significantly influence cardiac function and remodeling.
- Their roles in heart failure are complex, with H1R and H2R often exhibiting detrimental effects.
Purpose of the Study:
- To review the signaling pathways and functions of histamine receptors in normal cardiac physiology.
- To detail the known roles of histamine receptors in adverse cardiac remodeling and heart failure.
- To highlight the therapeutic potential of targeting histamine receptors for heart failure treatment.
Main Methods:
- Review of existing clinical studies and experimental animal models.
- Analysis of histamine receptor signaling mechanisms in cardiac cells (cardiomyocytes, fibroblasts, endothelial cells).
- Examination of the effects of histamine receptor activation/blockade on cardiac function and remodeling.
Main Results:
- Histamine 1 receptor activation shows detrimental effects, primarily in the coronary vasculature.
- Histamine 2 receptor activation is linked to adverse cardiac remodeling.
- Histamine 3 receptor activation suggests protective roles, while Histamine 4 receptor's role remains largely unknown.
Conclusions:
- Histamine receptors are critical players in the pathophysiology of heart failure.
- Targeting specific histamine receptors presents a promising avenue for heart failure drug repurposing and development.
- Further research into H3R and H4R functions in heart failure is warranted.
Related Concept Videos
Heart Failure II: Pathophysiology
103
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
103
Pathophysiology of Heart Failure
2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
574
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
574
Heart Failure Drugs: β-Blockers
487
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
487
Heart Failure V: Medical Management
52
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
52
Heart Failure I: Introduction
151
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
151

